BIIB

Report

Delayed Nasdaq - 04/16 04:00:00 pm
270.31	USD		-0.05%

04/17

BIOGEN : Aducanumab EMBARK study design poster at AAN 2021

04/16

BIOGEN : Grows Presence in China with the Approval of TECFIDERA (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

04/16

New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

04/12/2021	04/13/2021	04/14/2021	04/15/2021	04/16/2021	Date
262.8(c)	266.19(c)	265.79(c)	270.44(c)	270.31(c)	Last
753 596	823 301	697 428	986 472	999 778	Volume
-2.00%	+1.29%	-0.15%	+1.75%	-0.05%	Change

More quotes

Financials (USD)

Sales 2021	10 563 M - -
Net income 2021	2 303 M - -
Net Debt 2021	1 289 M - -
P/E ratio 2021	17,6x
Yield 2021	-

Sales 2022	10 593 M - -
Net income 2022	2 583 M - -
Net cash position 2022	462 M - -
P/E ratio 2022	15,0x
Yield 2022	-

Capitalization	40 696 M 40 696 M -
EV / Sales 2021	3,97x
EV / Sales 2022	3,80x
Nbr of Employees	9 100
Free-Float	85,9%

More Financials

Company

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment...

Sector

Pharmaceuticals

Calendar

04/22

Earnings Release

More about the company

Notations Surperformance© of Biogen Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about BIOGEN INC.

04/17	BIOGEN : Aducanumab EMBARK study design poster at AAN 2021	PU
04/16	BIOGEN : Grows Presence in China with the Approval of TECFIDERA (dimethyl fumar..	AQ
04/16	New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive I..	GL
04/15	BIOGEN : Wins Regulatory Approval in China for Tecfidera for Multiple Sclerosis	MT
04/15	STREET COLOR : Biogen Reportedly Receives Regulatory Nod in China for Relapsing ..	MT
04/15	BIOGEN : Grows Presence in China with the Approval of TECFIDERA® (dimethyl fuma..	AQ
04/15	Biogen Says Tecfidera Approved in China to Treat Relapsing Multiple Sclerosis	DJ
04/15	BIOGEN : to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster..	AQ
04/14	BIOGEN : Drug Updates of Particular Interest as Investors Await Q1 Results, Miz..	MT
04/14	Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster..	GL
04/12	BIOGEN : Wedbush Adjusts Price Target on Biogen to $245 From $236, Maintains Ne..	MT
04/12	SAGE THERAPEUTICS : Biogen Drug Candidate's Phase 2 Study in Essential Tremor M..	MT
04/12	Sage Therapeutics, Biogen Sees Positive Results for Essential Tremors Treatme..	DJ
04/12	BIOGEN : Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Control..	BU
04/09	BIOGEN INC. : Change in Directors or Principal Officers, Financial Statements a..	AQ

More news

News in other languages on BIOGEN INC.

04/07	Wall Street : pause dans une tendance demeurant très positive
04/06	Wall Street : pause dans une tendance demeurant très positive
03/30	Trois entreprises selon les critères de Warren Buffett
03/19	EEUU aprueba el tratamiento de la esclerosis múltiple de J&J, que se lanzará ..
03/16	Wall Street : bon début de semaine en attendant la Fed

More news

Analyst Recommendations on BIOGEN INC.

04/12	BIOGEN : Wedbush Adjusts Price Target on Biogen to $245 From $236, Maintains Ne..	MT
04/08	BIOGEN : RBC Capital Adjusts Biogen's Price Target to $263 From $257, Keeps Sec..	MT
02/17	BIOGEN : Cantor Fitzgerald Adjusts Biogen PT to $268 From $278, Maintains Neutr..	MT

More recommendations

Provided by Scoopnest.com

Analysis

U.S. FDA extends review period for Biogen's Alzheimer's drug to June

More Must read

Chart BIOGEN INC.

Duration : Period :

Biogen Inc. Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends BIOGEN INC.

	Short Term	Mid-Term	Long Term
Trends	Neutral	Bearish	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	HOLD
Number of Analysts	34
Average target price	291,50 $
Last Close Price	270,31 $
Spread / Highest target	69,4%
Spread / Average Target	7,84%
Spread / Lowest Target	-38,6%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Michel Vounatsos	Chief Executive Officer & Director
Michael R. McDonnell	Chief Financial Officer & Executive Vice President
Stelios Papadopoulos	Chairman
Alfred W. Sandrock	Executive Vice President-Research & Development
Mark Hernon	Chief Information Officer & Senior Vice President

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

BIOGEN INC.	10.45%	40 696



CSL LIMITED	-4.98%	94 687
WUXI BIOLOGICS (CAYMAN) INC.	2.14%	56 894
SAMSUNG BIOLOGICS CO.,LTD.	0.61%	49 298
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	18.65%	43 060
ALEXION PHARMACEUTICALS, INC.	4.76%	35 962

More Results